Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
AssigneeMassachusetts Institute of Technology
InventorsKarl Dane Wittrup, Byron Hua Kwan, Shuning Gai
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of treating cancer with a combination of extended-PK IL-2 and one or more therapeutic agents, such as a therapeutic antibody. The methods of the invention are applicable across any type of cancer.
Claims41
A method for treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of a fusion protein consisting of a human IL-2 moiety, an Fc domain and, optionally, a linker;
- and an effective amount of a therapeutic antibody.
A method of inhibiting growth and/or proliferation of tumor cells in a subject comprising administering an effective amount of a fusion protein consisting of a human IL-2 moiety, an Fc domain and, optionally, a linker;
- and an effective amount of a therapeutic antibody.
A method of increasing recruitment of lymphocytes to the periphery of a tumor in a subject comprising administering an effective amount of a fusion protein consisting of a human IL-2 moiety, an Fc domain and, optionally, a linker;
- and an effective amount of a therapeutic antibody.
A method of stimulating T cells and/or NK cells in a subject comprising administering an effective amount of a fusion protein consisting of a human IL-2 moiety, an Fc domain and, optionally, a linker;
- and an effective amount of a therapeutic antibody.
Dependencies are inferred from the claim text.